
...

By Gabe Whisnant
News Editor
0
Share
Newsweek is a Trust Project member
See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.
The Supreme Court on Monday extended access to the abortion pill mifepristone, keeping current rules in place while it considers whether to allow new restrictions to take effect.
The temporary order preserves one of the most common methods of abortion nationwide as the justices weigh a case that could reshape access years after Roe v. Wade was overturned. Women seeking medication abortions can continue obtaining the drug by mail or at pharmacies for now, even as the court prepares to decide whether to reinstate limits requiring in-person visits.

...
Read More on Politics
Justice Samuel Alito issued the brief administrative order, maintaining access to mifepristone until at least Thursday while the court reviews an emergency appeal tied to a Louisiana-led lawsuit. The move blocks a recent ruling by the 5th U.S. Circuit Court of Appeals that would have required patients to obtain the drug in person rather than through telehealth or mail prescriptions.
What the Supreme Court Order Does
Alito’s order leaves in place current Food and Drug Administration (FDA) rules that allow mifepristone to be prescribed remotely and dispensed by pharmacies or shipped to patients. Without the intervention, the appeals court ruling would have taken immediate effect nationwide, curbing access to a medication used in most U.S. abortions.
The order does not resolve the case but gives the justices more time to decide whether to extend the pause or allow the restrictions to take hold while litigation continues. As is typical in emergency applications, Alito did not provide a written explanation.
Louisiana Lawsuit Challenges FDA Rules
The case stems from a lawsuit filed by Louisiana seeking to roll back FDA policies that expanded access to mifepristone, arguing the rules undermine the state’s near-total abortion ban. State officials have also questioned the drug’s safety, despite decades of data supporting its use since its approval in 2000.
Lower courts sided in part with the state, concluding it is likely to succeed on the merits. A three-judge panel of the 5th Circuit then ordered that telehealth prescriptions and mail distribution be suspended while the case proceeds, prompting drug manufacturers to seek emergency relief from the Supreme Court.
Medication abortions—typically involving mifepristone followed by misoprostol—accounted for nearly two-thirds of all abortions in the United States as of 2023, underscoring the potential nationwide impact of the dispute.
Echoes of Prior Abortion Pill Fight
The legal battle mirrors an earlier challenge that reached the Supreme Court in the years after Roe was overturned. In that case, lower courts also attempted to restrict access to mifepristone in litigation brought by doctors who oppose abortion.
The Supreme Court stepped in to block those restrictions and later, in 2024, unanimously dismissed the challenge, finding the plaintiffs lacked legal standing to sue. The current case differs because it is led by a state, raising new questions about how federal drug regulations interact with state abortion bans.

...
Broader Stakes for Drug Policy and Politics
The dispute has drawn warnings from mainstream medical groups, pharmaceutical companies and Democratic lawmakers, who argue limiting access could destabilize the FDA’s drug approval system.
At the same time, abortion opponents have challenged mifepristone for decades through petitions and litigation, alleging the agency failed to properly evaluate safety risks. The FDA has repeatedly maintained the drug is safe and has eased restrictions over time, including expanding who can prescribe it and how it is distributed.
The Trump administration has taken an unusually quiet stance at the Supreme Court, declining to file a brief advising the justices, even though federal regulatory authority is central to the case. The silence has been interpreted by both sides as potentially favorable to the appellate ruling and underscores the political tension between anti-abortion constituencies and broader public support for abortion rights.
Alito, who wrote the 2022 decision ending constitutional protections for abortion, is handling the emergency appeal from the 5th Circuit. The full court is expected to act in the coming days on whether to extend the current access to mifepristone or allow new restrictions to take effect nationwide.
Trump Administration Unveils New Fertility Benefit Rule
Meanwhile, the Trump administration announced a new rule establishing a fertility benefit option that employers can offer workers outside traditional health insurance plans.
President Donald Trump unveiled the measure during an Oval Office event Monday, where Labor Department officials outlined the regulation. The administration has sought to expand affordability of fertility care, including a previously announced agreement with a drugmaker to reduce medication costs.
“The decline in birth rates is a serious challenge for our nation,” Health and Human Services Secretary Robert F. Kennedy Jr. said in a statement. “Under President Trump’s leadership, this rule expands access to fertility care and gives more Americans a real path to starting and growing their families. I appreciate my colleagues at the Departments of Labor and Treasury as we work together to deliver on this critical issue.”
View 0 Comments
Submit Correction
View Editorial & AI Guidelines